ATE427117T1 - Verwendung nativer peptide und deren optimierter derivate zur impfung - Google Patents
Verwendung nativer peptide und deren optimierter derivate zur impfungInfo
- Publication number
- ATE427117T1 ATE427117T1 AT06743108T AT06743108T ATE427117T1 AT E427117 T1 ATE427117 T1 AT E427117T1 AT 06743108 T AT06743108 T AT 06743108T AT 06743108 T AT06743108 T AT 06743108T AT E427117 T1 ATE427117 T1 AT E427117T1
- Authority
- AT
- Austria
- Prior art keywords
- vaccination
- optimized
- native
- peptides
- native peptides
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 6
- 238000002255 vaccination Methods 0.000 title abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 3
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 230000000840 anti-viral effect Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001122—Ephrin Receptors [Eph]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001186—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
- A61K39/001191—Melan-A/MART
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
- A61K39/001192—Glycoprotein 100 [Gp100]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464454—Enzymes
- A61K39/464457—Telomerase or [telomerase reverse transcriptase [TERT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/464486—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05290984 | 2005-05-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE427117T1 true ATE427117T1 (de) | 2009-04-15 |
Family
ID=37396914
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06743108T ATE427117T1 (de) | 2005-05-09 | 2006-05-09 | Verwendung nativer peptide und deren optimierter derivate zur impfung |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US8663645B2 (de) |
| EP (1) | EP1879612B1 (de) |
| JP (1) | JP5435938B2 (de) |
| CN (1) | CN101171032B (de) |
| AT (1) | ATE427117T1 (de) |
| BR (1) | BRPI0608768B1 (de) |
| CA (1) | CA2606871C (de) |
| DE (1) | DE602006006046D1 (de) |
| DK (1) | DK1879612T3 (de) |
| ES (1) | ES2323895T3 (de) |
| PL (1) | PL1879612T3 (de) |
| PT (1) | PT1879612E (de) |
| WO (1) | WO2006120038A2 (de) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008010010A1 (en) | 2006-07-12 | 2008-01-24 | Vaxon Biotech | Identification, optimization and use of cryptic hla-b7 epitopes for immunotherapy |
| CN102153658A (zh) * | 2011-01-19 | 2011-08-17 | 上海科医联创生物科技有限公司 | 肿瘤抗原、dc肿瘤疫苗及其制备方法 |
| US10258676B2 (en) * | 2011-09-06 | 2019-04-16 | Agency For Science, Technology And Research | Polypeptide vaccine |
| MA42420A (fr) | 2015-05-13 | 2018-05-23 | Agenus Inc | Vaccins pour le traitement et la prévention du cancer |
| EP3400959A1 (de) * | 2017-05-09 | 2018-11-14 | Vaxon Biotech | Verwendung eines impfstoffes zur abzielung auf ein kryptisches tert-epitop zur behandlung von krebs in einem hla-a*0201-positiven patienten mit einem nichtimmunogenen tumorexprimierenden tert |
| EP3400954A1 (de) * | 2017-05-09 | 2018-11-14 | Vaxon Biotech | Impfstoff zur abzielung auf ein kryptisches tert-epitop zur behandlung von lungenkrebs in einem hla-a*0201-positiven patienten, der nie oder weniger geraucht hat |
| US20200147195A1 (en) * | 2017-05-26 | 2020-05-14 | The Wistar Institute Of Anatomy And Biology | Dtert vaccines and methods of treatment using the same |
| MA52363A (fr) | 2018-04-26 | 2021-03-03 | Agenus Inc | Compositions peptidiques de liaison à une protéine de choc thermique (hsp) et leurs méthodes d'utilisation |
| US11161892B1 (en) | 2020-12-07 | 2021-11-02 | Think Therapeutics, Inc. | Method of compact peptide vaccines using residue optimization |
| US11058751B1 (en) | 2020-11-20 | 2021-07-13 | Think Therapeutics, Inc. | Compositions for optimized RAS peptide vaccines |
| US11421015B2 (en) | 2020-12-07 | 2022-08-23 | Think Therapeutics, Inc. | Method of compact peptide vaccines using residue optimization |
| US11464842B1 (en) | 2021-04-28 | 2022-10-11 | Think Therapeutics, Inc. | Compositions and method for optimized peptide vaccines using residue optimization |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001241533A1 (en) * | 2000-02-15 | 2001-08-27 | The Regents Of The University Of California | A universal vaccine and method for treating cancer employing telomerase reverse transcriptase |
| FR2812087B1 (fr) * | 2000-07-21 | 2007-05-11 | Inst Nat Sante Rech Med | Procede de criblage de peptides utilisables en immunotherapie |
| WO2003009812A2 (en) * | 2001-07-25 | 2003-02-06 | New York University | Use of glycosylceramides as adjuvants for vaccines against infections and cancer |
| FR2837837B1 (fr) * | 2002-03-28 | 2006-09-29 | Roussy Inst Gustave | Epitopes peptidiques communs a des antigenes d'une meme famille multigenique |
| FR2838742B1 (fr) | 2002-04-23 | 2004-07-09 | Inst Nat Sante Rech Med | Epitopes t de l'antigene epha2 |
-
2006
- 2006-05-09 BR BRPI0608768-0A patent/BRPI0608768B1/pt not_active IP Right Cessation
- 2006-05-09 DE DE602006006046T patent/DE602006006046D1/de active Active
- 2006-05-09 PT PT06743108T patent/PT1879612E/pt unknown
- 2006-05-09 US US11/913,138 patent/US8663645B2/en active Active
- 2006-05-09 CN CN2006800160112A patent/CN101171032B/zh not_active Expired - Fee Related
- 2006-05-09 JP JP2008510520A patent/JP5435938B2/ja active Active
- 2006-05-09 CA CA2606871A patent/CA2606871C/en active Active
- 2006-05-09 WO PCT/EP2006/005325 patent/WO2006120038A2/en not_active Application Discontinuation
- 2006-05-09 DK DK06743108T patent/DK1879612T3/da active
- 2006-05-09 PL PL06743108T patent/PL1879612T3/pl unknown
- 2006-05-09 EP EP06743108A patent/EP1879612B1/de active Active
- 2006-05-09 ES ES06743108T patent/ES2323895T3/es active Active
- 2006-05-09 AT AT06743108T patent/ATE427117T1/de active
-
2013
- 2013-12-06 US US14/099,881 patent/US20140178421A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0608768A2 (pt) | 2010-01-26 |
| EP1879612A2 (de) | 2008-01-23 |
| JP2008540483A (ja) | 2008-11-20 |
| CA2606871C (en) | 2014-06-03 |
| CN101171032B (zh) | 2012-02-29 |
| CN101171032A (zh) | 2008-04-30 |
| US20080254051A1 (en) | 2008-10-16 |
| PL1879612T3 (pl) | 2009-08-31 |
| PT1879612E (pt) | 2009-06-30 |
| JP5435938B2 (ja) | 2014-03-05 |
| BRPI0608768B1 (pt) | 2019-08-20 |
| CA2606871A1 (en) | 2006-11-16 |
| US20140178421A1 (en) | 2014-06-26 |
| US8663645B2 (en) | 2014-03-04 |
| DK1879612T3 (da) | 2009-07-20 |
| DE602006006046D1 (de) | 2009-05-14 |
| EP1879612B1 (de) | 2009-04-01 |
| ES2323895T3 (es) | 2009-07-27 |
| WO2006120038A2 (en) | 2006-11-16 |
| WO2006120038A3 (en) | 2007-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE427117T1 (de) | Verwendung nativer peptide und deren optimierter derivate zur impfung | |
| PH12020500396A1 (en) | Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) inhibitors and uses thereof | |
| WO2007039192A3 (en) | Compositions and methods for treating tumors presenting survivin antigens | |
| CY1121132T1 (el) | ΠΛΗΡΩΣ-ΑΝΘΡΩΠΙΝΑ ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ ANTI-vap-1 | |
| CY1117563T1 (el) | Αντισωματα κατα her3 και χρησεις αυτων | |
| BRPI0817299A8 (pt) | vacinas e componentes de vacina para inibição de células microbianas | |
| UA103751C2 (ru) | Иммуногенный пептид для иммунотерапии | |
| EP2228072A4 (de) | Krebsimpfstoff-zusammensetzung | |
| PH12013502192A1 (en) | Antibodies against human angiopoietin 2 | |
| BRPI0816405B8 (pt) | complexos de rna e pepitídeos catiônicos para transfecção e para imunoestimulação | |
| MY171854A (en) | Wt1 antigen peptide conjugate vaccine | |
| BR112014000466A2 (pt) | polipeptídeos quiméricos e híbridos fator viii, métodos de uso dos mesmos | |
| ATE404225T1 (de) | Radiofluorierte peptide | |
| EA200802170A1 (ru) | Лиофилизированная композиция терапевтического пептидного антитела | |
| CO6470802A2 (es) | Péptido auxiliar del antígeno del cáncer | |
| HK1139162A1 (en) | Cyclic receptor-associated protein (rap) peptides | |
| MX364777B (es) | Péptidos cancerígenos universales derivados de telomerasa. | |
| EA201170659A1 (ru) | Антитела к рецептору ii tgf-вета | |
| TR201903026T4 (tr) | S100a4 anti̇korlari ve bunlarin terapöti̇k kullanimlari. | |
| WO2008124646A3 (en) | Use of amyloid proteins as vaccine scaffolds | |
| ECSP099341A (es) | Nuevos anticuerpos antiproliferativos | |
| MX2009004243A (es) | Nuevas proteinas h5, moleculas de acido nucleico y vectores que las codifican y su uso medicinal. | |
| IL189452A0 (en) | Therapy with cd4 binding peptides and radiation | |
| CY1113726T1 (el) | Χρηση της πασιρεοτιδης για την αντιμετωπιση της ενδογενους υπερινσουλιναιμικης υπογλυκαιμιας | |
| CY1118967T1 (el) | Φαρμακευτικες συνθεσεις υψηλης δοσης βιοτινης |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1879612 Country of ref document: EP |